Listed by the USPTO as SALVOZA, M FRANCO G
Tech Center 1600 • Art Units: 1600 1632 1648 1653 1671 1672
This examiner grants 68% of resolved cases
SALVOZA, M FRANCO G is assigned to Tech Center 1600 and Art Unit 1600. The profile covers 628 resolved cases, with a 68.2% allowance rate and a 1156-day median to allowance. The case volume offers meaningful context for applicants, while the median timing indicates that prosecution may require multiple rounds of examination and response.
Interviews show a 30.6% lift in allowance outcomes. Practitioners may therefore consider interviews when they can connect a proposed amendment or technical explanation directly to the examiner's concern. The leading organizations are Dyno Therapeutics Inc., University of Houston System, and University of Florida Research Foundation Inc. Listed firms include Biospark Intellectual Property Law, Casimir Jones, S.C., and GOODWIN PROCTER LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17775206 | CRISPR COMPLEX-BASED DETECTION SYSTEM AND METHOD | Non-Final OA | University of Florida Research Foundation, Inc. |
| 19217607 | VECTOR-BASED GENE THERAPY FOR ELONGATOR ACETYLTRANSFERASE COMPLEX SUBUNIT 1 (ELP1) | Non-Final OA | University of Massachusetts |
| 18044568 | NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Final Rejection | Merck Patent GmbH |
| 18841498 | METHOD OF PRODUCING ADENO-ASSOCIATED VIRUS | Non-Final OA | KANEKA CORPORATION |
| 18027067 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | Non-Final OA | The Johns Hopkins University |
| 18757357 | GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17187678 | RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS | Non-Final OA | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA |
| 18837026 | SARS-COV-2 NEUTRALIZING SYNTHETIC PROTEINS | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18210829 | LIVE ATTENUATED ZIKA VIRUS WITH 3'UTR DELETION, VACCINE CONTAINING AND USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 18290089 | SARS-COV-2 IMMUNOASSAY METHOD AND IMMUNOASSAY KIT | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 17917058 | ASSAY TO DETECT VIRUS | Non-Final OA | CORNELL UNIVERSITY |
| 18000772 | MODIFIED ALPHAVIRUS FOR USE AS COVID-19 VACCINE | Non-Final OA | New York University |
| 18034312 | TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18017659 | TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18547842 | BOVINE VIRAL DIARRHEA VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION |
| 18577642 | METHOD FOR SURFACE EXPRESSION OF MEMBRANE PROTEINS THAT HAVE A CYTOPLASMIC C-TERMINAL TAIL | Non-Final OA | Capricor, Inc. |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | Non-Final OA | ASKBIO INC. |
| 18838888 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | Non-Final OA | NIPPON MEDICAL SCHOOL FOUNDATION |
| 18012284 | BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) | Non-Final OA | Navigo Proteins GmbH |
| 18023808 | ANTIBODY THERAPY | Non-Final OA | GENMAB A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.2% of resolved applications examined by M Franco G Salvoza were allowed (628 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +30.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by M Franco G Salvoza took 1,156 days on average from filing to allowance.
M Franco G Salvoza examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
